The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 501–600 of 1,006
Bellail, A. C., Jin, H. R., Lo, H.-Y., Jung, S. H., Hamdouchi, C., Kim, D., Higgins, R. K., Blanck, M., le Sage, C., Cross, B. C. S., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1486 · Cited by 42
Martinez-Høyer, S., Deng, Y., Parker, J., Jiang, J., Mo, A., Docking, T. R., Gharaee, N., Li, J., Umlandt, P., Fuller, M., et al. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0497-9 · Cited by 42
Cippitelli, M., Stabile, H., Kosta, A., Petillo, S., Gismondi, A., Santoni, A., & Fionda, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031103 · Cited by 42
“As part of their transcriptional program, Ikaros and Aiolos serve as anti-apoptotic transcription factors in MM cells and their loss causes reduced proliferation and cell death [7,8].”
BackgroundInfluentialTargeting NF-κB Signaling for Multiple Myeloma
Wong, A. H.-H., Shin, E. M., Tergaonkar, V., & Chng, W.-J. (2020) · Cancers · doi:10.3390/cancers12082203 · Cited by 42
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1
Wu, W., Nelson, G. M., Koch, R., Donovan, K. A., Nowak, R. P., Heavican-Foral, T. B., Nirmal, A. J., Liu, H., Yang, L., Duffy, J., et al. (2022) · Blood · doi:10.1182/blood.2021014701 · Cited by 39
E3-Specific Degrader Discovery by Dynamic Tracing of Substrate Receptor Abundance
Hanzl, A., Barone, E., Bauer, S., Yue, H., Nowak, R. P., Hahn, E., Pankevich, E. V., Koren, A., Kubicek, S., Fischer, E. S., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c10784 · Cited by 41
Applications of protein ubiquitylation and deubiquitylation in drug discovery
Chen, Y., Xue, H., & Jin, J. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107264 · Cited by 43
The Dihydroxy Metabolite of the Teratogen Thalidomide Causes Oxidative DNA Damage
Wani, T. H., Chakrabarty, A., Shibata, N., Yamazaki, H., Guengerich, F. P., & Chowdhury, G. (2017) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.7b00127 · Cited by 43
Cereblon Maintains Synaptic and Cognitive Function by Regulating BK Channel
Choi, T.-Y., Lee, S., Kim, Y.-J., Bae, J. R., Lee, K. M., Jo, Y., Kim, S., Lee, A.-R., Choi, S., Choi, L., et al. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.2081-17.2018 · Cited by 43
Perry, J. A., Seong, B. K. A., & Stegmaier, K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055710 · Cited by 42
Kunacheewa, C., & Orlowski, R. Z. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-112017-091045 · Cited by 43
Li, L., Xue, W., Shen, Z., Liu, J., Hu, M., Cheng, Z., Wang, Y., Chen, Y., Chang, H., Liu, Y., et al. (2020) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2020.06.013 · Cited by 40
Fischer, F., Grigolon, G., Benner, C., & Ristow, M. (2022) · Physiological Reviews · doi:10.1152/physrev.00017.2021 · Cited by 45
Kang, J., Park, S., Jeong, S. P., Han, M., Lee, C., Lee, K. M., Kim, N., Song, M., Choi, M., Ye, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502166113 · Cited by 46
Chemical Protein Degradation Approach and its Application to Epigenetic Targets
Itoh, Y. (2018) · The Chemical Record · doi:10.1002/tcr.201800032 · Cited by 42
Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance
Ho, M., Goh, C. Y., Patel, A. S., Staunton, S., O’Connor, R., Godeau, M., & Bianchi, G. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.05.026 · Cited by 43
Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
Yamamoto, L., Amodio, N., Gullà, A., & Anderson, K. C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.606368 · Cited by 42
Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
Liu, J., Peng, Y., & Wei, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.678077 · Cited by 47
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40
Li, F., Aljahdali, I. A. M., & Ling, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116206 · Cited by 36
Neri, P. E., Barwick, B. G., Jung, D., Patton, J. C., Maity, R., Tagoug, I., Stein, C. K., Tilmont, R., Leblay, N., Ahn, S., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0061 · Cited by 40
Chemical biology approaches to target validation in cancer
Blagg, J., & Workman, P. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.07.007 · Cited by 41
Pizzi, M., Boi, M., Bertoni, F., & Inghirami, G. (2016) · Leukemia · doi:10.1038/leu.2016.161 · Cited by 41
Lenalidomide in the treatment of chronic lymphocytic leukemia
Itchaki, G., & Brown, J. R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1313230 · Cited by 43
Ubiquitin-dependent regulation of transcription in development and disease
Mark, K. G., & Rapé, M. (2021) · EMBO Reports · doi:10.15252/embr.202051078 · Cited by 41
Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis
Ikura, H., Endo, J., Kitakata, H., Moriyama, H., Sano, M., & Fukuda, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116336 · Cited by 45
Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy
Li, X.-M., Zhao, Z., Xiao, Y., Xia, Q., Zhou, P., Wang, S., Wu, H., & Hu, J. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00394-2 · Cited by 41
Panobinostat: a review of trial results and future prospects in multiple myeloma
Libby, E. N., Becker, P. S., Burwick, N. R., Green, D. J., Holmberg, L., & Bensinger, W. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2015.983065 · Cited by 40
What influences the activity of Degrader−Antibody conjugates (DACs)
Guo, Y., Li, X., Xie, Y., & Wang, D. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116216 · Cited by 40
Zhang, H., Luo, X.-J., Yang, W., Wu, Z., Zhao, Z., Pei, X., Zhang, X., Chen, C., Lei, J. H., Shi, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53997-6 · Cited by 40
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer
Luo, J., Chen, Z., Qiao, Y., Tien, J. C.-Y., Young, E., Mannan, R., Mahapatra, S., Bhattacharyya, R., Xiao, L., He, T., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02336-6 · Cited by 43
The development of potential antibody-based therapies for myeloma
Sherbenou, D. W., Behrens, C. R., Yang, S., Wolf, J. L., Martin, T. G., & Liu, B. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.09.011 · Cited by 39
SPLINTS: small-molecule protein ligand interface stabilizers
Fischer, E. S., Park, E., Eck, M. J., & Thomä, N. H. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.01.004 · Cited by 39
Nishimura, N., Radwan, M. O., Amano, M., Endo, S., Fujii, E., Hayashi, H., Ueno, S., Ueno, N., Tatetsu, H., Hata, H., et al. (2019) · Cancer Science · doi:10.1111/cas.14154 · Cited by 41
Piechotta, V., Jakob, T., Langer, P. H., Monsef, I., Scheid, C., Estcourt, L. J., Ocheni, S., Theurich, S., Kuhr, K., Scheckel, B., et al. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013487 · Cited by 42
Crbn modulates calcium influx by regulating Orai1 during efferocytosis
Moon, H., Min, C., Kim, G., Kim, D., Kim, K., Lee, S.-A., Moon, B., Yang, S., Lee, J., Yang, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19272-0 · Cited by 42
CRL4CRBN E3 Ligase Complex as a Therapeutic Target in Multiple Myeloma
Barankiewicz, J., Salomon‐Perzyński, A., Misiewicz-Krzemińska, I., & Lech‐Marańda, E. (2022) · Cancers · doi:10.3390/cancers14184492 · Cited by 42
Krasavin, M., Adamchik, M., Bubyrev, A. I., Heim, C., Maiwald, S. A., Zhukovsky, D., Zhmurov, P. A., Bunev, A. S., & Hartmann, M. D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114990 · Cited by 41
The Drug Vehicle and Solvent N-Methylpyrrolidone Is an Immunomodulator and Antimyeloma Compound
Shortt, J., Hsu, A., Martin, B. P., Doggett, K., Matthews, G. M., Doyle, M., Ellul, J., Jockel, T. E., Andrews, D. M., Hogg, S. J., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.008 · Cited by 42
Unraveling the mysteries of plasma cells
Schuh, W., Mielenz, D., & Jäck, H. (2020) · Advances in immunology · doi:10.1016/bs.ai.2020.01.002 · Cited by 41
Goh, W., Sudholz, H., Foroutan, M., Scheer, S., Pfefferle, A., Delconte, R. B., Meng, X., Shen, Z., Hennessey, R., Kong, I. Y., et al. (2024) · Nature Immunology · doi:10.1038/s41590-023-01718-4 · Cited by 38
London, N. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00570 · Cited by 39
Lenalidomide and secondary acute lymphoblastic leukemia: a case series
Tan, M., Fong, R., Lo, M., & Young, R. (2015) · Hematological Oncology · doi:10.1002/hon.2248 · Cited by 38
From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma
Licht, J. D., Shortt, J., & Johnstone, R. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.019 · Cited by 37
Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera
Kim, K., Lee, D. H., Park, S., Jo, S.-H., Ku, B., Park, S. G., Park, B. C., Jeon, Y. U., Ahn, S., Kang, C. H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56177-5 · Cited by 36
Linkage-specific ubiquitin chain formation depends on a lysine hydrocarbon ruler
Liwocha, J., Krist, D. T., van Noort, G. J. V. D. H., Hansen, F. M., Truong, V. H., Karayel, Ö., Purser, N., Houston, D., Burton, N., Bostock, M. J., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00696-0 · Cited by 40
Maneiro, M., Vita, E. D., Conole, D., Kounde, C. S., Zhang, Q., & Tate, E. W. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.002 · Cited by 41
Designing HDAC-PROTACs: Lessons Learned So Far
Fischer, F., Avelar, L. A. A., Murray, L., & Kurz, T. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0206 · Cited by 38
PROTAC: targeted drug strategy. Principles and limitations
Koroleva, O. A., Dutikova, Y. V., Trubnikov, A. V., Zenov, F. A., Manasova, E. V., Shtil, A. A., & Kurkin, A. V. (2022) · Russian Chemical Bulletin · doi:10.1007/s11172-022-3659-z · Cited by 41
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
Targeting the Ubiquitin System in Glioblastoma
Scholz, N., Kurian, K. M., Siebzehnrübl, F. A., & Licchesi, J. D. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574011 · Cited by 37
The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma
Paradžik, T., Bandini, C., Mereu, E., Labrador, M., Taìana, E., Amodio, N., Neri, A., & Piva, R. (2021) · Cancers · doi:10.3390/cancers13061235 · Cited by 39
A PROTAC targets splicing factor 3B1
Gama-Brambila, R. A., Chen, J., Zhou, J., Tascher, G., Münch, C., & Cheng, X. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.018 · Cited by 39
Tateno, S., Iida, M., Fujii, S., Suwa, T., Katayama, M., Tokuyama, H., Yamamoto, J., Ito, T., Sakamoto, S., Handa, H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-61027-w · Cited by 36
A small-molecule VHL molecular glue degrader for cysteine dioxygenase 1
Tutter, A., Buckley, D., Golosov, A. A., Ma, X., Shu, W., McKay, D. J. J., Darsigny, V., Dovala, D., Beckwith, R., Solomon, J., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01936-x · Cited by 36
Cryo-electron microscopy-based drug design
Cebi, E., Lee, J., Subramani, V. K., Bak, N., Oh, C., & Kim, K. K. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1342179 · Cited by 38
Implications of frequent hitter E3 ligases in targeted protein degradation screens
Zhang, X., Simon, G. M., & Cravatt, B. F. (2025) · Nature Chemical Biology · doi:10.1038/s41589-024-01821-z · Cited by 37
IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas
Bandini, C., Pupuleku, A., Spaccarotella, E., Pellegrino, E., Wang, R., Vitale, N., Duval, C., Cantarella, D., Rinaldi, A., Provero, P., et al. (2018) · Cancers · doi:10.3390/cancers10010021 · Cited by 37
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy
Wirth, M., Schick, M., Keller, U. B., & Krönke, J. (2020) · Cancers · doi:10.3390/cancers12123764 · Cited by 36
Kiehlmeier, S., Rafiee, M., Bakr, A., Mika, J., Kruse, S., Müller, J., Schweiggert, S., Herrmann, C., Sigismondo, G., Schmezer, P., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01235-z · Cited by 37
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318259 · Cited by 36
Ward, J. P., Berrien-Elliott, M. M., Gomez, F., Luo, J. R., Becker‐Hapak, M., Cashen, A. F., Wagner‐Johnston, N. D., Maddocks, K. J., Mosior, M., Foster, M., et al. (2021) · Blood · doi:10.1182/blood.2021011894 · Cited by 36
Ligand-induced degrons for studying nuclear functions
Kanemaki, M. T. (2022) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2021.12.006 · Cited by 36
Zhang, D., Harris, H. M., Chen, J., Judy, J., James, G., Kelly, A., McIntosh, J., Tenn-McClellan, A., Ambing, E., Tan, Y. S., et al. (2023) · Blood · doi:10.1182/blood.2022016934 · Cited by 35
Keersmaecker, B. D., Fostier, K., Corthals, J., Wilgenhof, S., Heirman, C., Aerts, J. L., Thielemans, K., & Schots, R. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1571-6 · Cited by 35
Ligand-induced genetic degradation as a tool for target validation
Yesbolatova, A., Tominari, Y., & Kanemaki, M. T. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.11.001 · Cited by 35
Roy, A. L., Prébet, T., Castellano, R., Goubard, A., Riccardi, F., Fauriat, C., Granjeaud, S., Benyamine, A., Castanier, C., Orlanducci, F., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00977 · Cited by 36
Protein degraders - from thalidomide to new PROTACs
Ito, T. (2023) · The Journal of Biochemistry · doi:10.1093/jb/mvad113 · Cited by 36
Simplifying Access to Targeted Protein Degraders via Nickel Electrocatalytic Cross‐Coupling
Neigenfind, P., Massaro, L., Péter, Á., Degnan, A. P., Emmanuel, M. A., Oderinde, M. S., He, C., Peters, D., Ewing, T. E., Kawamata, Y., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202319856 · Cited by 34
Tan, L., & Gray, N. S. (2018) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800293 · Cited by 35
Translating the anti-myeloma activity of Natural Killer cells into clinical application
Fionda, C., Stabile, H., Molfetta, R., Soriani, A., Bernardini, G., Zingoni, A., Gismondi, A., Paolini, R., Cippitelli, M., & Santoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.005 · Cited by 36
Schiedel, M., Moroglu, M., Ascough, D. M. H., Chamberlain, A. E. R., Kamps, J. J. A. G., Sekirnik, A. R., & Conway, S. J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201812164 · Cited by 37
Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
Wang, Q., Shao, X., Leung, E. L., Chen, Y., & Yao, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105804 · Cited by 36
SJPYT-195: A Designed Nuclear Receptor Degrader That Functions as a Molecular Glue Degrader of GSPT1
Huber, A. D., Li, Y., Lin, W., Galbraith, A. N., Mishra, A., Porter, S. N., Wu, J., Gee, R. R. F., Zhuang, W., Pruett‐Miller, S. M., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00223 · Cited by 37
A biotin targeting chimera (BioTAC) system to map small molecule interactomes in situ
Tao, A. J., Jiang, J., Gadbois, G. E., Goyal, P., Boyle, B. T., Mumby, E. J., Myers, S. A., English, J. G., & Ferguson, F. M. (2023) · Nature Communications · doi:10.1038/s41467-023-43507-5 · Cited by 38
Bourgeois, W., Cutler, J. A., Aubrey, B. J., Wenge, D. V., Perner, F., Martucci, C., Henrich, J. A., Klega, K. S., Nowak, R. P., Donovan, K. A., et al. (2023) · Blood · doi:10.1182/blood.2023021105 · Cited by 35
Gu, D., Wang, S., Kuiatse, I., Wang, H., He, J., Dai, Y., Jones, R. J., Bjorklund, C. C., Yang, J., Grant, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103015 · Cited by 34
Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma
Shi, C.-X., Kortüm, K. M., Zhu, Y. X., Jedlowski, P. M., Bruins, L. A., Braggio, E., & Stewart, A. K. (2015) · Haematologica · doi:10.3324/haematol.2015.124297 · Cited by 34
PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4
Ueno, N., Nishimura, N., Ueno, S., Endo, S., Tatetsu, H., Hirata, S., Hata, H., Matsuoka, M., Mitsuya, H., & Okuno, Y. (2017) · Oncogene · doi:10.1038/onc.2017.79 · Cited by 34
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
Design and Development of IKZF2 and CK1α Dual Degraders
Miyamoto, D. K., Curnutt, N. M., Park, S., Stavropoulos, A., Kharas, M. G., & Woo, C. M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01736 · Cited by 35
Yokoo, H., Shibata, N., Endo, A., Ito, T., Yanase, Y., Murakami, Y., Fujii, K., Hamamura, K., Saeki, Y., Naito, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01206 · Cited by 33
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptors
Whalen, K. A., Rakhra, K., Mehta, N. K., Steinle, A., Michaelson, J. S., & Baeuerle, P. A. (2023) · mAbs · doi:10.1080/19420862.2023.2208697 · Cited by 34
Bolomsky, A., Schreder, M., Meißner, T., Hose, D., Ludwig, H., Pfeifer, S., & Zojer, N. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.03.005 · Cited by 34
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
Steger, M., Nishiguchi, G., Wu, Q., Schwalb, B., Shashikadze, B., McGowan, K., Actis, M., Aggarwal, A., Shi, Z., Price, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62829-0 · Cited by 32
“IMiDs bind to cereblon (CRBN), a substrate recognition subunit of CRL4 CRBN ligase 5 , and induce degradation of the transcription factors IKZF1 and IKZF3 that are required for multiplemyelomacell survival 6,7 .”
Costa, L. J., Fanning, S. R., Stephenson, J., Afrin, L. B., Kistner‐Griffin, E., Bentz, T. A., & Stuart, R. K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.935369 · Cited by 32
The Role of Immunotherapy in Multiple Myeloma
Kocoglu, M. H., & Badros, A. Z. (2016) · Pharmaceuticals · doi:10.3390/ph9010003 · Cited by 42
Small molecule-mediated protein knockdown as a new approach to drug discovery
Tinworth, C. P., Lithgow, H., & Churcher, I. (2016) · MedChemComm · doi:10.1039/c6md00347h · Cited by 31
Tuning the proteasome to brighten the end of the journey
Mayor, T., Sharon, M., & Glickman, M. H. (2016) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00198.2016 · Cited by 32
Xiao, D., Wang, Y.-J., Hu, X., Kan, W., Zhang, Q., Jiang, X., Zhou, Y., Li, J. X., & Lu, W. P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.035 · Cited by 33
Small-molecule PROTACs: Novel Agents for Cancer Therapy
Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 33
FBXW7 Triggers Degradation of KMT2D to Favor Growth of Diffuse Large B-cell Lymphoma Cells
Saffie, R., Zhou, N., Rolland, D. C. M., Önder, Ö., Basrur, V., Campbell, S. L., Wellen, K. E., Elenitoba‐Johnson, K. S. J., Capell, B. C., & Busino, L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2247 · Cited by 33
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 34
Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2021) · Cancers · doi:10.3390/cancers13184666 · Cited by 34
Molecular glues: enhanced protein-protein interactions and cell proteome editing
Weagel, E. G., Foulks, J. M., Siddiqui, A. Q., & Warner, S. L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02882-2 · Cited by 33
Lim, Y. S., Yoo, S.-M., Patil, V., Kim, H. W., Kim, H.-H., Suh, B., Park, J. Y., Jeong, N.-R., Park, C. H., Ryu, J. H., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008121 · Cited by 32
Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling
Ng, A., Offensperger, F., Cisneros, J. A., Scholes, N. S., Malik, M., Villanti, L., Rukavina, A., Ferrada, E., Hannich, J. T., Koren, A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00598 · Cited by 35
McGraw, K. L., Basiorka, A. A., Johnson, J., Clark, J., Cáceres, G., Padron, E., Heaton, R., Ozawa, Y., Wei, S., Sokol, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114249 · Cited by 32
Costa, F., Vescovini, R., Bolzoni, M., Marchica, V., Storti, P., Toscani, D., Accardi, F., Notarfranchi, L., Palma, B. D., Manferdini, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18085 · Cited by 36
Jonasova, A., Bokorova, R., Polak, J., Vostry, M., Kostecka, A., Hajkova, H., Neuwirtova, R., Siskova, M., Sponerova, D., Cermak, J., et al. (2015) · European Journal of Haematology · doi:10.1111/ejh.12457 · Cited by 31
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.